Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
Research Centre for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Artillerivej, Copenhagen, Denmark.
J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):166-172. doi: 10.1093/jpids/piy142.
Maternal priming might enhance the beneficial nonspecific effects (NSEs) of live measles vaccination (MV). Children with a bacillus Calmette-Guérin (BCG) vaccine scar have a lower mortality rate than those without a scar that is not explained by protection against tuberculosis. We examined the hypothesis that BCG scarring would have a stronger effect on a child if the mother also had a BCG scar.
In a randomized controlled trial (RCT) of early MV in children aged 4.5 months, the BCG-scar status of the children and their mother were registered at enrollment at 4.5 months of age. The children were followed up until they were 36 months of age. Using a Cox proportional hazards model, we compared mortality rate ratios according to maternal and child BCG-scar status after adjusting for where the BCG vaccine was given (the national hospital or elsewhere). We censored for other interventions that have immunomodulating effects on child survival, including neonatal vitamin A supplementation and early MV.
A total of 2213 children had not received neonatal vitamin A supplementation and early MV; 83% of these children and 44% of the mothers had a BCG scar. Children whose mother had a BCG scar were not more likely to have a BCG scar than those whose mother did not have a BCG scar (risk ratio, 1.01 [95% confidence interval (CI), 0.98-1.05]). Among the children, having a BCG scar was associated with a 41% (95% CI, 5%-64%) lower mortality between the ages of 4.5 and 36 months. The reduction in mortality was 66% (95% CI, 33%-83%) if the mother also had a BCG scar but only 8% (95% CI, -83% to 53%) if the mother had no BCG scar (test of interaction, P = .04).
Maternal BCG priming might be important for the effect of BCG vaccination on child survival. Ensuring better BCG vaccine scarring among mothers and children could have a considerable effect on child mortality levels.
母体致敏可能会增强活麻疹疫苗接种(MV)的有益非特异性效应(NSEs)。与没有卡介苗(BCG)疫苗疤痕的儿童相比,有 BCG 疫苗疤痕的儿童死亡率较低,而这种差异不能用预防结核病来解释。我们检验了这样一个假设,即在母亲也有 BCG 疤痕的情况下,BCG 疤痕对儿童的影响会更强。
在一项针对 4.5 个月大儿童的早期 MV 的随机对照试验(RCT)中,在儿童 4.5 个月大时登记儿童及其母亲的 BCG 疤痕状况。对儿童进行随访,直到他们 36 个月大。使用 Cox 比例风险模型,我们比较了根据母亲和儿童 BCG 疤痕状况的死亡率比,调整了 BCG 疫苗接种地点(国家医院或其他地方)。我们对其他具有免疫调节作用的儿童生存的干预措施进行了删失,包括新生儿维生素 A 补充和早期 MV。
共有 2213 名儿童未接受新生儿维生素 A 补充和早期 MV;其中 83%的儿童和 44%的母亲有 BCG 疤痕。与母亲没有 BCG 疤痕的儿童相比,母亲有 BCG 疤痕的儿童更不可能有 BCG 疤痕(风险比,1.01 [95%置信区间(CI),0.98-1.05])。在儿童中,BCG 疤痕与 4.5 至 36 个月期间的死亡率降低 41%(95%CI,5%-64%)相关。如果母亲也有 BCG 疤痕,死亡率降低 66%(95%CI,33%-83%),但如果母亲没有 BCG 疤痕,则死亡率降低 8%(95%CI,-83%至 53%)(交互检验,P=0.04)。
母体 BCG 致敏可能对 BCG 疫苗接种对儿童生存的影响很重要。确保母亲和儿童更好地形成 BCG 疫苗疤痕可能会对儿童死亡率水平产生重大影响。